Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection

Overview of attention for article published in BMC Gastroenterology, February 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (66th percentile)
Good Attention Score compared to outputs of the same age and source (65th percentile)

Mentioned by

twitter: 1 X user

wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 4 Dimensions

Readers on

mendeley: 37 Mendeley

Summary X Wikipedia Dimensions citations

So far, Dimensions has found 4 publications that cite this research output.

4

The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.

Targeting the SARS-CoV-2 spike glycoprotein prefusion conformation: virtual screening and molecular dynamics simulations applied to the identification of potential fusion inhibitors

Article in Virus Research (June 2020)

NS5B polymerase inhibitors in phase II clinical trials for HCV infection

Article in Expert Opinion on Investigational Drugs (December 2017)

Virology analysis in HCV genotype 1-infected patients treated with the combination of simeprevir and TMC647055/ritonavir, with and without ribavirin, and JNJ-56914845

Article in Virology Journal (May 2017)